ImmuCell Corp's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 110/158 in the Pharmaceuticals industry.Institutional ownership is very high.In the medium term, the stock price is expected to remain stable.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
ImmuCell Corp's Score
Industry at a Glance
Industry Ranking
110 / 158
Overall Ranking
310 / 4582
Industry
Pharmaceuticals
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
0
analysts
--
Current Rating
0.000
Target Price
0.00%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
ImmuCell Corp Highlights
StrengthsRisks
ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 42.68% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 26.49M.
Overvalued
The company’s latest PE is 21.77, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 1.81M shares, decreasing 4.46% quarter-over-quarter.
ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).
Ticker SymbolICCC
CompanyImmuCell Corp
CEOte Boekhorst (Olivier)
Websitehttps://immucell.com/
FAQs
What is the current price of ImmuCell Corp (ICCC)?
The current price of ImmuCell Corp (ICCC) is 5.970.
What is the symbol of ImmuCell Corp?
The ticker symbol of ImmuCell Corp is ICCC.
What is the 52-week high of ImmuCell Corp?
The 52-week high of ImmuCell Corp is 7.600.
What is the 52-week low of ImmuCell Corp?
The 52-week low of ImmuCell Corp is 4.280.
What is the market capitalization of ImmuCell Corp?
The market capitalization of ImmuCell Corp is 54.00M.
What is the net income of ImmuCell Corp?
The net income of ImmuCell Corp is -2.16M.
Is ImmuCell Corp (ICCC) currently rated as Buy, Hold, or Sell?
According to analysts, ImmuCell Corp (ICCC) has an overall rating of --, with a price target of --.
What is the Earnings Per Share (EPS TTM) of ImmuCell Corp (ICCC)?
The Earnings Per Share (EPS TTM) of ImmuCell Corp (ICCC) is 0.274.